JP7818838B2 - 二重特異性抗体およびその適用 - Google Patents

二重特異性抗体およびその適用

Info

Publication number
JP7818838B2
JP7818838B2 JP2023535529A JP2023535529A JP7818838B2 JP 7818838 B2 JP7818838 B2 JP 7818838B2 JP 2023535529 A JP2023535529 A JP 2023535529A JP 2023535529 A JP2023535529 A JP 2023535529A JP 7818838 B2 JP7818838 B2 JP 7818838B2
Authority
JP
Japan
Prior art keywords
chain
combination
mutations
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023535529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552851A (ja
JP2023552851A5 (cg-RX-API-DMAC7.html
Inventor
シャンドン チー
Original Assignee
クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド filed Critical クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド
Publication of JP2023552851A publication Critical patent/JP2023552851A/ja
Publication of JP2023552851A5 publication Critical patent/JP2023552851A5/ja
Application granted granted Critical
Publication of JP7818838B2 publication Critical patent/JP7818838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023535529A 2019-12-09 2021-05-19 二重特異性抗体およびその適用 Active JP7818838B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911253241 2019-12-09
CN202011427863.9A CN113135996A (zh) 2019-12-09 2020-12-09 一种双特异抗体及其应用
CN202011427863.9 2020-12-09
PCT/CN2021/094672 WO2022121239A1 (zh) 2019-12-09 2021-05-19 一种双特异性抗体及其应用

Publications (3)

Publication Number Publication Date
JP2023552851A JP2023552851A (ja) 2023-12-19
JP2023552851A5 JP2023552851A5 (cg-RX-API-DMAC7.html) 2024-01-15
JP7818838B2 true JP7818838B2 (ja) 2026-02-24

Family

ID=76809347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535529A Active JP7818838B2 (ja) 2019-12-09 2021-05-19 二重特異性抗体およびその適用

Country Status (5)

Country Link
US (1) US20240043567A1 (cg-RX-API-DMAC7.html)
EP (1) EP4261231A4 (cg-RX-API-DMAC7.html)
JP (1) JP7818838B2 (cg-RX-API-DMAC7.html)
CN (1) CN113135996A (cg-RX-API-DMAC7.html)
WO (1) WO2022121239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110054701B (zh) * 2019-04-17 2022-12-27 中国医学科学院血液病医院(血液学研究所) 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
AU2022261268A1 (en) * 2021-04-22 2023-11-16 Guangdong Fapon Biopharma Inc. Bispecific multifunctional fusion polypeptide
US20240294640A1 (en) * 2021-06-02 2024-09-05 Qure Biotechnology (Shanghai) Co., Ltd. Anti-cd3 antibody variant, fusion protein, and application
US20250206823A1 (en) * 2021-07-30 2025-06-26 Qure Biotechnology (Shanghai) Co., Ltd. Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof
CN116284430A (zh) * 2021-07-30 2023-06-23 广东菲鹏制药股份有限公司 靶向肿瘤的il15融合蛋白及其应用
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
CN113817065B (zh) * 2021-09-06 2023-04-18 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
WO2023036270A1 (zh) * 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023046093A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物
WO2023046116A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种白介素15及其受体的多肽复合物
CN116262786B (zh) * 2021-12-13 2026-05-15 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
CN116496408A (zh) * 2022-01-21 2023-07-28 广东菲鹏制药股份有限公司 白细胞介素21及其受体复合物
CN115246885B (zh) * 2022-06-30 2023-10-24 盛禾(中国)生物制药有限公司 一种双特异性抗体及其应用
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
WO2026114362A1 (zh) * 2024-11-29 2026-06-04 正大天晴药业集团股份有限公司 抗体-偶联物、其制备方法及应用
CN119775429B (zh) * 2024-12-26 2026-08-07 南开大学 一种抗人her2/ccr4的双特异性抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541335A (ja) 2010-09-21 2013-11-14 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019057122A1 (en) 2017-09-22 2019-03-28 Wuxi Biologics (Shanghai) Co., Ltd. NEW BISPECIFIC POLYPEPTIDE COMPLEXES
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
JP6510532B2 (ja) * 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性her2抗体及び使用方法
EP3093295B1 (en) * 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
US10905743B2 (en) * 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
EP3464352B1 (en) * 2016-05-27 2021-03-24 Altor BioScience Corporation Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
US11168138B2 (en) * 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
KR20210003814A (ko) * 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
WO2019204646A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
US20220143178A1 (en) * 2019-02-03 2022-05-12 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-her2 bispecific antibody and application thereof
JP7621263B2 (ja) * 2019-02-22 2025-01-24 武▲漢▼友芝友生物制▲薬▼股▲ふん▼有限公司 改変されたFc断片、それを含む抗体、及びそれらの使用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541335A (ja) 2010-09-21 2013-11-14 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019057122A1 (en) 2017-09-22 2019-03-28 Wuxi Biologics (Shanghai) Co., Ltd. NEW BISPECIFIC POLYPEPTIDE COMPLEXES
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Simon Krah et al.,New Biotechnology,2017年,Vol.39,p.167-173

Also Published As

Publication number Publication date
WO2022121239A1 (zh) 2022-06-16
JP2023552851A (ja) 2023-12-19
EP4261231A1 (en) 2023-10-18
EP4261231A4 (en) 2024-11-13
CN113135996A (zh) 2021-07-20
US20240043567A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
EP4261231A1 (en) Bispecific antibody and application thereof
JP2023552851A5 (cg-RX-API-DMAC7.html)
US12269885B2 (en) Anti-PD-L1/VEGF bifunctional antibody and use thereof
WO2018233574A1 (zh) 一种抗pd-l1人源化纳米抗体及其应用
CN109575140A (zh) 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
AU2025275202A1 (en) Interleukin-2 Mutant And Fusion Protein Thereof
CN109721657A (zh) 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
US20250000946A1 (en) Il-2 variants and fusion proteins thereof
WO2021219127A1 (zh) 一种靶向her2和pd-1的双特异性抗体及其应用
IL323964A (en) Multispecific antibody targeting c-met
US20250333507A1 (en) Fusion protein of anti-tigit antibody and il2 or variant thereof, and application thereof
EP4683949A1 (en) Tnf superfamily member immunocytokine and uses thereof
WO2024078479A1 (zh) 一种异源二聚体融合蛋白及其应用
RU2652880C2 (ru) Антитело против рецептора эпидермального фактора роста
CN103172741B (zh) 全人源抗egfr抗体
WO2024199458A1 (en) Il-2 variants with improved stability and compositions thereof
HK40060665A (en) Anti-pd-l1/vegf bifunctional antibody and use thereof
CN118894943A (zh) 靶向密蛋白的双特异性抗体
WO2023219120A1 (ja) 抗cd37-抗cd3二重特異性抗体
CN121064335A (zh) 结合ror1和cd3的双特异性抗体及其用途
CN121910895A (zh) 靶向EGFR和c-Met的抗体药物偶联物
WO2021244552A1 (zh) 抗pdl1×kdr的双特异性抗体
CN111484554A (zh) 一种靶向4-1bb的肿瘤抑制性抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260203

R150 Certificate of patent or registration of utility model

Ref document number: 7818838

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150